Evaluate SurVaxM plus standard of care versus placebo plus standard of care in newly diagnosed glioblastoma, with overall survival as the primary endpoint.
Approach:
Design: Randomized, double-blind, placebo-controlled, multicenter Phase 2b trial (NCT05163080) with 233 evaluable patients at 11 U.S. cancer centers.
Endpoints: Overall survival was the primary endpoint; patients aged 65 and under were a prespecified key subgroup. Secondary endpoints included progression-free survival, landmark survival, safety, and immune responses.
Key Findings:
In all evaluable patients, median overall survival was 22.8 months with SurVaxM versus 20.3 months with placebo (HR 0.75; 95% CI 0.54–1.03; adjusted p=0.076), not meeting the conventional p<0.05 threshold.
Among patients aged 65 and under, median overall survival was 24.2 versus 20.2 months (HR 0.64; 95% CI 0.44–0.93; adjusted p=0.019).
In the same age subgroup, progression-free survival favored SurVaxM (HR 0.64; p=0.018); 12-month progression-free survival was 44% versus 24%.
Among SurVaxM-treated patients aged 65 and under, approximately 42% were alive at 30 months or longer, compared with 18% in the placebo group.
Adverse events were predominantly Grade 1 or 2 injection-site reactions and influenza-like illness. Grade 3 or higher adverse-event rates were 48% with SurVaxM and 46% with placebo; no treatment-related deaths were reported.
Interpretation:
The trial did not show a statistically significant overall-survival difference in the full evaluable population, while the prespecified subgroup aged 65 and under had statistically significant overall- and progression-free-survival results. The placebo group’s median overall survival was 20.3 months, above the 16-month historical benchmark used in the trial’s design.
Limitations:
The reported results are an initial analysis from the fully enrolled trial; the article states that continued follow-up is warranted for long-term survival.
The overall-population primary endpoint did not reach the conventional threshold for statistical significance.
The source is a company announcement and does not provide a full trial report or detailed subgroup sample sizes.
Conclusion:
MimiVax plans to request an FDA meeting to discuss the results and potential regulatory pathways, including expedited pathways.
Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.
